Microbiome and MicroRNA or Long Non-Coding RNA-Two Modern Approaches to Understanding Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is one of humans' most common and fatal neoplasms. Nowadays, a number of PDAC studies are being conducted in two different fields: non-coding RNA (especially microRNA and long non-coding RNA) and microbiota. It has been recently discovered that not only does miRNA affect particular bacteria in the gut microbiome that can promote carcinogenesis in the pancreas, but the microbiome also has a visible impact on the miRNA. This suggests that it is possible to use the combined impact of the microbiome and noncoding RNA to suppress the development of PDAC. Nevertheless, insufficient research has focused on bounding both approaches to the diagnosis, treatment, and prevention of pancreatic ductal adenocarcinoma. In this article, we summarize the recent literature on the molecular basis of carcinogenesis in the pancreas, the two-sided impact of particular types of non-coding RNA and the pancreatic cancer microbiome, and possible medical implications of the discovered phenomenon.

Automated summary

Pancreatic ductal adenocarcinoma (PDAC) is a common and fatal neoplasm in humans. Current research focuses on two fields: non-coding RNA (especially microRNA and long non-coding RNA) and the microbiota. Recent findings show that miRNA can affect specific bacteria in the gut microbiome that contribute to pancreatic carcinogenesis, and the microbiome can also impact miRNA expression. Combining the microbiome and non-coding RNA may offer potential strategies for suppressing PDAC development, but more research is needed to fully understand and utilize these approaches for diagnosis, treatment, and prevention.